Integromics Announces New Version of SeqSolve™ NGS Analysis Software
Complete the form below to unlock access to ALL audio articles.
Integromics® has announced the release of the second version of SeqSolve™, its analytical solution for Next Generation Sequencing (NGS) data.
The latest version of Integromics’ SeqSolve features custom and proprietary annotations, new applications for ChIP-seq and RNA-seq analyzes including alternative splicing, significant improvements of the RNA-seq analysis, new gene discovery, and transcript-level differential expression.
Combining automatic Click and Go® workflow with Cufflinks algorithms (Trapnell et al., 2010, Nature Biotech), SeqSolve is the first software product that enables biologists to perform cutting edge transcriptome analysis simply.
“Currently, analytical software used in the NGS field is developed by computational, not experimental scientists. The result is Linux/Unix-based tools, which are often not created with the biologist or the bioinformatician end-user in mind,” said Dr. Michael J. McManus, CEO, Integromics.
Dr. McManus continued, “The latest version of SeqSolve has been designed by Integromics in collaboration with top pharmaceutical companies to address their scientists’ expectations. Integromics has been able to bridge the gap between Linux command-line software and user-friendly bioinformatics applications.”
Integromics has delivered pharmaceutical company requests by including a custom annotations loader to extend the scope of the application to any species and proprietary genome annotations.
This includes integrating bioinformatics methods published in peer-reviewed scientific literature (Cufflinks, SAMtools, IGV Genome Browser, MACS) in a user-friendly graphical interface essential for less computationally-oriented biologists. Also, a client/server version has been implemented for large-scale scientific projects and will be publicly available in October.
The estimated market for Next-Generation Sequencing technologies is USD 480 million in 2008, USD 746 million in 2010 and USD 3 billion in 2017 (Frost and Sullivan Report, Dec 2010; JASON Report for the U.S. DoD, Dec 2010).
The capacity of extracting biological information from the generated data has now become a “major bottleneck of critical importance” (BBSRC Review, Feb. 2011).
Recent user surveys state the most important improvement in the area of NGS is reported to be “better analytical tools”, above "decreasing cost", "improving accuracy" and dramatically reducing the time for analysis.
This is a key bottleneck for use on personal genomes in a clinical setting (Davies, Bio-IT World, Sept. 2010).
